ophthalmic innovation 2016 - "a view from the aao"
TRANSCRIPT
Ophthalmic Innovation 2016:A View from the AAO
David W. Parke II, M.D.
CEO
American Academy of Ophthalmology
2
The Big Three
• V2V: “VOLUME TO VALUE”
• A2A: “ANECDOTES” TO “ANALYTICS”
• P2P: “PATIENTS TO POPULATIONS”
3
V2V: Health Care Payments
VALUE = QUALITYCOST
VALUE = healthcare outcomes achieved per dollar spent
4
Measuring the ‘Right Stuff’
• What is the most important factor in surgery?
1. Judgment as to whether to operate or not2. Which procedure to perform given clinical factors3. Intraoperative technical skill4. Whether guidelines followed for antimicrobial prophylaxis
5
MACRA
Fundamentally changes the way Medicare determines and updates payments to physicians (and hospitals and ASC’s)
Goes into effect January 2017 Final rules this week
6
Impact for Industry• Within three years, 30% of each ophthalmologist’s individual score
will be based on “resource use” or total cost• Cataract surgery: site of service (ASC vs HOPD)• Retina: choice of anti-VEGF agent
• Impact on physician payment and behavior:• up to 9% of total Medicare payments at risk
7
A2A: Anecdotes 2 Analytics: IRIS Sept 2016
4173
041
944
4200
542
064
4212
542
186
4224
842
30942
35342
38542
46142
53742
629
0
20
40
60
80
100
120
Patient Visits Unique Patients
Timeline
Mill
ions
8
CMS Penalties Avoided by IRISYear Physicians MFS PQRS
PenaltyVBMPenalty
MUPenalty
Total
2014 4,130 $338,000 $27.9M $27.9M $55.8M
2015 10,800 $338,000 $73.0M $73M – $146M $109.5M $255.5M-$328.5M
2016 12,000 $338,000 $81.1M $81M – $162M $121.7M $283.9M-$365M
2017 12,000 $338,000 $81.1M $81M – $162M $121.7M $283.9M-$365M
2018 12,000 $338,000 $81.1M $81M – $162M $162.2M $283.9-$405.6M
9
IRIS Impact: New Knowledge to Measure “Value”
• Natural history data
• Prevalence data
• Treatment impacts
• Drug interactions
• Complications
• Rare diseases
10
Big Numbers 2013-June 2016
• Cataract surgery• 3,738,937 eyes• 2,356,159 unique patients
• Primary open-angle glaucoma• 3,251,938 unique patients
11
Big Numbers 2013-June 2016• AMD diagnosis
• 2,230,755 unique patients
• Anti-VEGF injections• 4,468,969 injections• 577,048 unique patients
• Diabetic retinopathy• 1,220,770 unique patients
• Rebranding—AAO and the profession• Communicating externally• Engaging the patient• Demonstrating value• Thinking about populations of patients
P2P: Patients to Populations:Repositioning the Profession
14
EyeSmart Audience GrowthQ
1 20
11
Q2
2011
Q3
2011
Q4
2011
Q1
2012
Q2
2012
Q3
2012
Q4
2012
Q1
2013
Q2
2013
Q3
2013
Q4
2013
Q1
2014
Q2
2014
Q3
2014
Q4
2014
Q1
2015
Q2
2015
Q3
2015
Q4
2015
Q1
2016
Q2
2016
Q3
2016
0
500,000
1,000,000
1,500,000
2,000,000
2,500,000
3,000,000
3,500,000
Visitors
• Data represents monthly totals combined for each quarter• Q3 2016 is projected
15
August: Callie’s story
16
NASEM Study: Reprioritizing Eye Health
• Examine the core principles and public health strategies to reduce visual impairment and promote eye health in the United States.
• Action plan for public and private collaborations at the community, state, and national levels to elevate vision and eye health as a public health issue.
18